Gene Therapy Targeting PCSK9

The last decades of research in cardiovascular prevention have been characterized by successful bench-to-bedside developments for the treatment of low-density lipoprotein (LDL) hypercholesterolemia. Recent examples include the inhibition of proprotein convertase subtilisin/kexin type 9 (PCSK9) with...

Descripción completa

Detalles Bibliográficos
Autores principales: Katzmann, Julius L., Cupido, Arjen J., Laufs, Ulrich
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8781734/
https://www.ncbi.nlm.nih.gov/pubmed/35050192
http://dx.doi.org/10.3390/metabo12010070

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8781734/
https://www.ncbi.nlm.nih.gov/pubmed/35050192
http://dx.doi.org/10.3390/metabo12010070

Ejemplares similares